Africa bears a disproportionate burden of viral haemorrhagic fevers. Sudan virus, Marburg virus, Crimean-Congo haemorrhagic fever, and Lassa fever collectively kill thousands of people across the continent each year, yet they remain among the most underfunded areas of vaccine research globally. The reasons are well-documented: small market sizes, geographically concentrated outbreaks, and the high biosafety containment requirements (BSL-4) needed to work with these pathogens all contribute to a persistent research gap. Against this backdrop, the March 2026 publication from KU Leuven's Rega Institute is not merely a scientific curiosity — it is a potential turning point for Africa's neglected disease vaccine pipeline.
The study, led by Lara Kelchtermans, Yeranddy A. Alpizar, and Professor Kai Dallmeier, demonstrated in a mouse model of Sudan virus infection that CD4-T cells — not neutralising antibodies — are the critical mediators of vaccine-induced protection. This finding challenges the antibody-centric paradigm that has dominated vaccine development for decades and raises a fundamental question: how many promising vaccine candidates for Africa's neglected pathogens have been abandoned prematurely because they failed to generate sufficient antibody titres, even though they may have induced robust cellular immunity?
The Antibody Trap in Neglected Disease Vaccine Research
The reliance on antibody titres as the primary endpoint in vaccine trials is understandable from a practical standpoint. Antibody assays are standardised, reproducible, relatively inexpensive, and can be performed in lower-biosafety settings. For pathogens like influenza and SARS-CoV-2, where the correlation between antibody levels and protection is well-established, this approach is scientifically justified. But for filoviruses, arenaviruses, and other BSL-4 pathogens endemic to Africa, the immunological correlates of protection are far less well-defined.
The KU Leuven study provides a concrete example of how this gap can mislead vaccine development. Their experimental Sudan virus vaccine induced antibodies — the expected outcome — but when the researchers disrupted antibody function or transferred antibodies via serum to naive animals, protection was lost. The vaccine's efficacy resided entirely in a cellular mechanism mediated by CD4-T cells. Had this vaccine been evaluated solely on antibody induction in a standard immunogenicity study, it might have appeared promising. Had it been evaluated on antibody neutralisation alone as a correlate of protection, the true mechanism of its efficacy would have been invisible.
What Are CD4-T Cells, and Why Do They Matter for Filoviral Vaccines?
CD4-T cells, or T helper cells, are a subset of lymphocytes that play a central coordinating role in adaptive immunity. They recognise pathogen-derived peptides presented on MHC class II molecules — found primarily on antigen-presenting cells such as dendritic cells and macrophages — and respond by secreting cytokines that orchestrate the broader immune response. In classical immunology, CD4-T cells are understood primarily as helpers: they activate B cells to produce antibodies and provide co-stimulatory signals to CD8-T cells (cytotoxic T lymphocytes) that directly kill infected cells.
The KU Leuven study suggests that in the context of Sudan virus infection, CD4-T cells play a more direct and autonomous protective role. Yeranddy A. Alpizar described this dual function: CD4-T cells act simultaneously as orchestrators of the acute antiviral response and as modulators that prevent the immune system from causing excessive tissue damage. This immunomodulatory function is particularly relevant for filoviral infections, where cytokine storm — an uncontrolled inflammatory response — is a major driver of the haemorrhagic manifestations and multi-organ failure that characterise severe disease.
A vaccine that elicits CD4-T cells capable of both fighting the virus and dampening immunopathology would represent a qualitatively superior product compared to one that merely induces antibodies. For Africa's filoviral disease burden, this distinction is not academic — it is the difference between a vaccine that saves lives and one that provides incomplete or fragile protection.
Lessons for the Sudan Virus, Marburg, and Lassa Fever Vaccine Pipelines
The Sudan virus vaccine pipeline is thin. While significant progress has been made on Zaire Ebola virus vaccines — with the rVSV-ZEBOV (Ervebo) vaccine approved by the FDA and EMA — Sudan virus has no licensed vaccine. Several candidates are in early development, including ChAd3-SUDV and a modified vaccinia Ankara (MVA)-based candidate, but none has completed Phase 3 trials. The KU Leuven findings suggest that the evaluation of these candidates should be expanded to include comprehensive cellular immunity assessments, particularly CD4-T cell quantification and functional assays.
The same logic applies to Marburg virus, for which two vaccine candidates (cAd3-Marburg and rVSV-MARV) are in clinical trials following the 2023 Equatorial Guinea outbreak. Lassa fever vaccine development is even further behind, with no candidate beyond Phase 2. In each of these cases, the immunological correlates of protection are poorly defined, and the KU Leuven study provides a compelling scientific rationale for investing in cellular immunity research as a complement to antibody-based evaluation.
Integrating AI and Data Informatics into Next-Generation Vaccine Evaluation
As someone working at the intersection of molecular microbiology, biosafety, and AI-driven data informatics, I see a clear opportunity to apply computational tools to this challenge. Machine learning models trained on multi-dimensional immune response data — incorporating antibody titres, CD4-T cell counts, CD8-T cell activity, cytokine profiles, and clinical outcomes — could identify the true correlates of protection for individual pathogens far more efficiently than traditional univariate approaches. This kind of systems immunology approach, powered by AI, could transform how we evaluate and prioritise vaccine candidates for Africa's neglected diseases.
The KU Leuven study is a single data point — a mouse model, not a human clinical trial. But it is a data point that demands attention. It calls on the global vaccine research community to broaden its immunological lens, to invest in cellular immunity assays alongside antibody studies, and to resist the temptation to reduce the complexity of immune protection to a single metric. Africa's communities, who bear the greatest burden of these diseases, deserve nothing less than the most rigorous and comprehensive approach to vaccine science.